The "guardian of the genome"—An old key to unlock the ERCC1 issue

Luc Friboulet; Jean Charles Soria; Ken Andre Olaussen

doi:10.1158/1078-0432.CCR-18-4123

The "guardian of the genome"—An old key to unlock the ERCC1 issue

Luc Friboulet, Jean Charles Soria, Ken Andre Olaussen

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts (ISA) and interstrand cross-links, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.

langue originale	Anglais
Pages (de - à)	2369-2371
Nombre de pages	3
journal	Clinical Cancer Research
Volume	25
Numéro de publication	8
Les DOIs	https://doi.org/10.1158/1078-0432.CCR-18-4123
état	Publié - 15 avr. 2019

Accès au document

10.1158/1078-0432.CCR-18-4123

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7659c5303d394484913d84d0efae21f8,

title = "The {"}guardian of the genome{"}—An old key to unlock the ERCC1 issue",

abstract = "Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts (ISA) and interstrand cross-links, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.",

author = "Luc Friboulet and Soria, {Jean Charles} and Olaussen, {Ken Andre}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = apr,

day = "15",

doi = "10.1158/1078-0432.CCR-18-4123",

language = "English",

volume = "25",

pages = "2369--2371",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "8",

}

TY - JOUR

T1 - The "guardian of the genome"—An old key to unlock the ERCC1 issue

AU - Friboulet, Luc

AU - Soria, Jean Charles

AU - Olaussen, Ken Andre

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts (ISA) and interstrand cross-links, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.

AB - Excision Repair Cross-Complementation Group 1 (ERCC1) participates in the repair of DNA intrastrand adducts (ISA) and interstrand cross-links, but its role as a predictive biomarker has never been fully validated. It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85064829153&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-4123

DO - 10.1158/1078-0432.CCR-18-4123

M3 - Article

C2 - 30728154

AN - SCOPUS:85064829153

SN - 1078-0432

VL - 25

SP - 2369

EP - 2371

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 8

ER -